Publications by authors named "Elisa Ignatius"

Claim this Profile
S
Structure of a Bronchiectasis and NTM Care Center: a Position Statement by the Bronchiectasis & NTM Association.
Patrick Flume, Wendy Bullington, Lily Christon, Eva Crawford, Alyssa Ditner, Elisa Ignatius

Chest· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2C clinical trial of novel short-course regimens for the treatment of pulmonary tuberculosis: TBTC study 38/CRUSH-TB design.
Ekaterina V Kurbatova, Kelly E Dooley, Wendy Carr, Jason E Stout, Eric L Nuermberger, Elisa Ignatius

Contemp Clin Trials· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ACTG A5409 (RAD-TB): Study protocol for a phase 2 randomized, adaptive, dose-ranging, open-label trial of novel regimens for the treatment of pulmonary tuberculosis.
Linda J Harrison, Gustavo E Velásquez, Russell R Kempker, Marjorie Z Imperial, Eric Nuermberger, Elisa Ignatius

Trials· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ACTG A5409 (RAD-TB): Study Protocol for a Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis.
Linda Harrison, Gustavo E Velasquez, Russell R Kempker, Marjorie Z Imperial, Eric Nuermberger, Elisa Ignatius

Res Sq· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical Trial.
Kamunkhwala Gausi, Elisa H Ignatius, Veronique De Jager, Caryn Upton, Soyeon Kim

Am J Respir Crit Care Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacies of omadacycline + amikacin + imipenem and an all-oral regimen omadacycline + clofazimine + linezolid in a mouse model of lung disease.
Elisa H Ignatius, Binayak Rimal, Chandra M Panthi, Daniel C Belz, Christopher K Lippincott

mSphere· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacies of three drug regimens containing omadacycline to treat Mycobacteroides abscessus disease.
Binayak Rimal, Chandra M Panthi, Yi Xie, Daniel C Belz, Elisa H Ignatius

Tuberculosis (Edinb)· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-Containing Regimens for Drug-Sensitive Tuberculosis: 12-Week Results.
Kelly E Dooley, Bronwyn Hendricks, Nikhil Gupte, Grace Barnes, Kim Narunsky, Elisa H Ignatius

Am J Respir Crit Care Med· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Omadacycline-Containing Regimen in a Mouse Model of Pulmonary Mycobacteroides abscessus Disease.
Binayak Rimal, Danielle A Nicklas, Chandra M Panthi, Christopher K Lippincott, Daniel C Belz, Elisa H Ignatius

mSphere· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis.
Kamunkhwala Gausi, Maxwell Chirehwa, Elisa H Ignatius, Richard Court, Xin Sun

J Antimicrob Chemother· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nebulized Bacteriophage in a Patient With Refractory Lung Disease.
Rebekah M Dedrick, Krista G Freeman, Jan A Nguyen, Asli Bahadirli-Talbott, Mitchell E Cardin, Elisa H Ignatius

Open Forum Infect Dis· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Semimechanistic Model of the Bactericidal Activity of High-Dose Isoniazid against Multidrug-Resistant Tuberculosis: Results from a Randomized Clinical Trial.
Kamunkhwala Gausi, Elisa H Ignatius, Xin Sun, Soyeon Kim, Laura Moran

Am J Respir Crit Care Med· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A leap forward in assessing host-directed therapies for tuberculosis.
Elisa H Ignatius, Kelly E Dooley

Lancet Respir Med· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PrEParing for long-acting injectable PrEP in the South: perspectives from healthcare providers in Georgia.
Casey D Xavier Hall, Justin C Smith, Robert A Driggers, Bethany Stoller, Zara Khan, Elisa H Ignatius

AIDS Care· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A validated liquid chromatography tandem mass spectrometry assay for the analysis of pretomanid in plasma samples from pulmonary tuberculosis patients.
Andisiwe Malo, Tracy Kellermann, Elisa H Ignatius, Kelly E Dooley, Rodney Dawson

J Pharm Biomed Anal· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pretomanid Pharmacokinetics in the Presence of Rifamycins: Interim Results from a Randomized Trial among Patients with Tuberculosis.
Elisa H Ignatius, Mahmoud Tareq Abdelwahab, Bronwyn Hendricks, Nikhil Gupte, Kim Narunsky

Antimicrob Agents Chemother· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tocilizumab for the Treatment of COVID-19 Among Hospitalized Patients: A Matched Retrospective Cohort Analysis.
Elisa H Ignatius, Kunbo Wang, Andrew Karaba, Matthew Robinson, Robin K Avery

Open Forum Infect Dis· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are We There Yet? Short-Course Regimens in TB and HIV: From Prevention to Treatment of Latent to XDR TB.
Elisa H Ignatius, Susan Swindells

Curr HIV/AIDS Rep· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Getting to the point in point-of-care diagnostics for tuberculosis.
Elisa H Ignatius, Keira A Cohen, William R Bishai

J Clin Invest· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Bactericidal Activity of Different Isoniazid Doses for Drug-Resistant Tuberculosis (INHindsight): A Randomized, Open-Label Clinical Trial.
Kelly E Dooley, Sachiko Miyahara, Florian von Groote-Bidlingmaier, Xin Sun, Richard Hafner, Elisa H Ignatius

Am J Respir Crit Care Med· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to Decroo : High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis.
Kelly E Dooley, Sachiko Miyahara, Florian von Groote-Bidlingmaier, Xin Sun, Richard Hafner, Elisa H Ignatius

Am J Respir Crit Care Med· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New Drugs for the Treatment of Tuberculosis.
Elisa H Ignatius, Kelly E Dooley

Clin Chest Med· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study.
Elize Pietersen, Elisa Ignatius, Elizabeth M Streicher, Barbara Mastrapa, Xavier Padanilam

Lancet· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis